Stock listing
NASDAQ:DMAC DiaMedica Therapeutics Inc. Stock
Home listing (NASDAQ) of DiaMedica Therapeutics Inc.
Follow DiaMedica Therapeutics Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:DMAC
$8.25 USD -0.34 (-4.0%)
Close on Nov 20, 2026
- Day range
- $7.88 – $8.39 USDNov 20, 2026
- Volume
- 313,537 sharesNov 20, 2026
- Market cap
- $445.1M USDAt the close on Nov 20, 2026 · price × 53.96M shares outstanding
- 52-week range
- $5.25 – $11.00 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $1.66M USDMedian day 187,300 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:DMAC · Home | $8.25 USD | -0.34 (-4.0%) | 313,537 | $7.91 | $8.39 | $7.88 | $8.59 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:DMAC · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $8.25 | -0.34 | -4.0% | $7.91 | $8.39 | $7.88 | 313,537 | |
| $8.59 | +0.21 | +2.5% | $8.40 | $8.91 | $8.40 | 205,936 | |
| $8.38 | +0.05 | +0.6% | $8.38 | $8.635 | $7.90 | 294,961 | |
| $8.33 | -0.46 | -5.2% | $8.65 | $9.305 | $8.27 | 246,370 | |
| $8.79 | -0.54 | -5.8% | $9.22 | $9.22 | $8.11 | 214,091 | |
| $9.33 | -0.33 | -3.4% | $9.53 | $9.59 | $9.05 | 186,621 | |
| $9.66 | -0.01 | -0.1% | $9.72 | $9.85 | $9.53 | 139,358 | |
| $9.67 | +0.02 | +0.2% | $9.645 | $9.86 | $9.21 | 144,931 | |
| $9.65 | +0.29 | +3.1% | $9.64 | $9.92 | $9.42 | 144,642 | |
| $9.36 | +0.32 | +3.5% | $9.10 | $9.739 | $9.055 | 156,754 | |
| $9.04 | -1.73 | -16.1% | $10.70 | $10.84 | $8.98 | 330,456 | |
| $10.77 | +0.77 | +7.7% | $10.15 | $11.00 | $10.15 | 407,079 | |
| $10.00 | +0.71 | +7.6% | $9.38 | $10.04 | $9.38 | 302,393 | |
| $9.29 | +0.04 | +0.4% | $9.47 | $9.505 | $8.96 | 141,466 | |
| $9.25 | -0.27 | -2.8% | $9.39 | $9.54 | $9.165 | 174,646 | |
| $9.52 | -0.30 | -3.1% | $9.83 | $9.985 | $9.42 | 196,416 | |
| $9.82 | +1.13 | +13.0% | $8.71 | $10.13 | $8.60 | 519,652 | |
| $8.69 | -0.05 | -0.6% | $8.72 | $8.72 | $8.30 | 268,714 | |
| $8.74 | +0.02 | +0.2% | $8.77 | $8.92 | $8.56 | 129,603 | |
| $8.72 | +0.09 | +1.0% | $8.55 | $8.79 | $8.29 | 110,029 | |
| $8.63 | -0.06 | -0.7% | $8.70 | $8.946 | $8.51 | 87,987 | |
| $8.69 | +0.02 | +0.2% | $8.72 | $8.95 | $8.59 | 155,377 | |
| $8.67 | +0.80 | +10.2% | $7.88 | $8.87 | $7.88 | 168,169 | |
| $7.87 | +0.30 | +4.0% | $7.78 | $7.99 | $7.60 | 188,583 | |
| $7.57 | -0.47 | -5.8% | $8.04 | $8.10 | $7.53 | 260,800 | |
| $8.04 | +0.38 | +5.0% | $7.82 | $8.24 | $7.66 | 303,900 | |
| $7.66 | -0.16 | -2.0% | $7.68 | $8.02 | $7.61 | 287,000 | |
| $7.82 | -0.38 | -4.6% | $8.21 | $8.21 | $7.72 | 256,000 | |
| $8.20 | -0.13 | -1.6% | $8.26 | $8.335 | $7.945 | 185,600 | |
| $8.33 | +0.32 | +4.0% | $8.00 | $8.45 | $8.00 | 170,200 | |
| $8.01 | +0.02 | +0.3% | $7.92 | $8.06 | $7.66 | 240,300 | |
| $7.99 | -0.14 | -1.7% | $8.01 | $8.415 | $7.95 | 221,200 | |
| $8.13 | -0.29 | -3.4% | $8.50 | $8.61 | $8.05 | 242,300 | |
| $8.42 | +0.19 | +2.3% | $8.23 | $8.63 | $8.19 | 231,400 | |
| $8.23 | -0.12 | -1.4% | $8.49 | $8.61 | $8.02 | 335,700 | |
| $8.35 | +0.08 | +1.0% | $8.33 | $8.54 | $8.10 | 234,200 | |
| $8.27 | +0.07 | +0.9% | $8.27 | $8.60 | $8.19 | 219,100 | |
| $8.20 | -0.12 | -1.4% | $8.30 | $8.381 | $8.03 | 231,100 | |
| $8.32 | +0.38 | +4.8% | $7.86 | $8.55 | $7.789 | 362,800 | |
| $7.94 | +0.11 | +1.4% | $7.85 | $8.00 | $7.44 | 236,400 | |
| $7.83 | +0.27 | +3.6% | $7.57 | $7.89 | $7.43 | 209,200 | |
| $7.56 | -0.22 | -2.8% | $7.70 | $7.75 | $7.34 | 174,100 | |
| $7.78 | +0.52 | +7.2% | $7.34 | $7.80 | $7.30 | 312,100 | |
| $7.26 | +0.41 | +6.0% | $6.86 | $7.35 | $6.825 | 281,800 | |
| $6.85 | 0.00 | 0.0% | $6.85 | $6.94 | $6.755 | 195,000 | |
| $6.85 | +0.22 | +3.3% | $6.75 | $7.00 | $6.675 | 257,800 | |
| $6.63 | +0.10 | +1.5% | $6.55 | $6.74 | $6.46 | 187,300 | |
| $6.53 | -0.02 | -0.3% | $6.55 | $6.65 | $6.36 | 157,900 | |
| $6.55 | +0.08 | +1.2% | $6.49 | $6.65 | $6.44 | 145,600 | |
| $6.47 | 0.00 | 0.0% | $6.57 | $6.877 | $6.33 | 123,600 | |
| $6.47 | -0.12 | -1.8% | $6.57 | $6.665 | $6.30 | 182,400 | |
| $6.59 | +0.05 | +0.8% | $6.50 | $6.974 | $6.50 | 167,100 | |
| $6.54 | -0.21 | -3.1% | $6.70 | $6.71 | $6.53 | 119,100 | |
| $6.75 | +0.19 | +2.9% | $6.56 | $6.887 | $6.49 | 189,500 | |
| $6.56 | -0.19 | -2.8% | $6.78 | $6.79 | $6.525 | 116,100 | |
| $6.75 | +0.30 | +4.7% | $6.60 | $6.935 | $6.59 | 176,000 | |
| $6.45 | +0.10 | +1.6% | $6.29 | $6.45 | $6.265 | 145,900 | |
| $6.35 | -0.04 | -0.6% | $6.44 | $6.59 | $6.22 | 135,100 | |
| $6.39 | -0.36 | -5.3% | $6.72 | $6.74 | $6.34 | 116,500 | |
| $6.75 | +0.05 | +0.7% | $6.68 | $6.80 | $6.56 | 113,800 | |
| $6.70 | -0.04 | -0.6% | $6.66 | $6.76 | $6.62 | 118,300 | |
| $6.74 | +0.22 | +3.4% | $6.60 | $6.865 | $6.60 | 130,900 | |
| $6.52 | 0.00 | 0.0% | $6.53 | $6.57 | $6.32 | 84,700 | |
| $6.52 | 0.00 | 0.0% | $6.58 | $6.73 | $6.50 | 77,600 | |
| $6.52 | -0.29 | -4.3% | $6.77 | $6.90 | $6.42 | 130,900 |
Splits
1 split · NASDAQ:DMAC · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-20 | Consolidation |
- Ticker
- NASDAQ:DMAC
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 12, 2026
DiaMedica Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights
Latest earnings call · Nov 13, 2026
DiaMedica Therapeutics (NASDAQ:DMAC) Q3 2026 Earnings Call
Replay and transcript
Latest deck · November 2026
Investor Presentation (November 2026)
Investor deck · 38 slides
Latest news
DiaMedica Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights
Nov 12, 2026
Closed $8.79 (-5.8%) on Nov 13, 2026
DiaMedica Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Business Update November 13, 2026
Nov 5, 2026
Closed $9.04 (-16.1%) on Nov 5, 2026
DiaMedica Therapeutics Announces Enrollment of 200th Patient in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial
Oct 22, 2026
Closed $8.63 (-0.7%) on Oct 22, 2026
DiaMedica Therapeutics Provides Update on Fetal Growth Restriction Key Opinion Leader Webinar
Oct 19, 2026
Closed $7.87 (+4.0%) on Oct 19, 2026
DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 for Fetal Growth Restriction Featuring Early Phase 2 FGR Results
Sep 30, 2026
Closed $8.27 (+0.9%) on Sep 30, 2026
DiaMedica Therapeutics to Participate in Upcoming September Investor Conferences
Sep 2, 2026
Closed $6.75 (+4.7%) on Sep 2, 2026
DiaMedica Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights
Aug 10, 2026
Closed $6.87 (+3.3%) on Aug 11, 2026
DiaMedica Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Business Update August 11, 2026
Aug 4, 2026
Closed $6.67 (+1.9%) on Aug 5, 2026
DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction
Jun 23, 2026
Closed $6.28 (+6.6%) on Jun 23, 2026
DiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program
Jun 16, 2026
Closed $5.69 (+1.1%) on Jun 16, 2026
DiaMedica Therapeutics Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 22 in the last 12 months · 141 in all · newest Nov 12, 2026 · oldest 2019
- Calls
- 25 calls with a replay · 25 with a transcript · latest Nov 13, 2026
- Decks
- 14 decks · latest November 2026
Where DiaMedica Therapeutics Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:DMAC · Home listing · This page | NASDAQ | United States | USD |
| BOATS:DMAC | BOATS | United States | USD |
Valuation
Price/book 15.5× against a median of 2.4×: 9th lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $410.4M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 15.5×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.67
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| DiaMedica Therapeutics Inc. · NASDAQ:DMAC | US$445.1M | US$410.4M | n/a | n/a | n/a | 15.5× | n/a | 0.0× | 1.67 |
| Assembly Biosciences, Inc. · NASDAQ:ASMB | US$454.4M | US$142.3M | n/a | 2.1× | n/a | 1.5× | −16.6% | 0.0× | 1.00 |
| Shattuck Labs, Inc. · NASDAQ:STTK | US$454.2M | US$260.4M | n/a | n/a | n/a | 2.4× | n/a | 0.0× | 1.10 |
| G2GBIO, Inc. · KRX:456160 | US$449.1M | US$289.0M | n/a | 176× | n/a | 4.3× | −793.7% | 0.0× | n/a |
| CytomX Therapeutics, Inc. · NASDAQ:CTMX | US$442.5M | US$98.96M | n/a | 7.0× | n/a | 1.6× | −609.0% | 0.0× | 1.21 |
| Capricor Therapeutics, Inc. · NASDAQ:CAPR | US$441.3M | US$335.9M | n/a | n/a | n/a | 2.1× | n/a | 0.4× | 0.94 |
| Hansa Biopharma AB · OMXSTO:HNSA | US$440.9M | US$488.0M | n/a | 26.3× | n/a | n/a | −406.5% | n/a | n/a |
| Shanghai MicuRx Pharmaceutical Co., Ltd. Class A · SSE:688373 | US$439.3M | US$408.1M | n/a | 16.2× | n/a | 19.4× | −57.0% | 0.9× | n/a |
| Clarity Pharmaceuticals Ltd. · ASX:CU6 | US$437.1M | US$239.0M | n/a | n/a | n/a | 3.5× | n/a | 0.0× | n/a |
| Hyundai Bioscience Co. Ltd. · KRX:048410 | US$435.2M | US$408.8M | n/a | 166× | n/a | 5.7× | −861.5% | 0.1× | n/a |
| Oculis Holding AG · NASDAQ:OCS | US$434.8M | US$184.3M | n/a | 22,112× | n/a | 1.8× | n/a | 0.0× | 0.99 |
| Median of the others | US$441.1M | US$274.7M | 26.3× | 2.4× | −507.7% | 0.0× | 1.00 |
Forecasts
5 strong buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 15.50 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.81 · 4 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Rick Pauls | President & CEO |
| Scott Kellen | Chief Financial Officer |
| Ambarish Shah | Chief Technology Officer |
| Dominic Cundari | Chief Commercial Officer |
| Julie Krop | Chief Medical Officer |
Board
| Director | Role |
|---|---|
| James Parsons | Chairman of the Board |
| Charles Semba | Director |
| Daniel O’Connor | Director |
| Michael Giuffre | Director |
| Richard Kuntz | Director |
| Rick Pauls | President & CEO |
| Tanya Lewis | Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| DiaMedica Therapeutics (NASDAQ:DMAC) Q3 2026 Earnings Call | Fri, Nov 13, 2026 · 8:00 AM ET | Replay |
| DiaMedica Therapeutics (NASDAQ:DMAC) Q2 2026 Earnings Call | Tue, Aug 11, 2026 · 8:00 AM ET | Replay |
| DiaMedica Therapeutics (NASDAQ:DMAC) Q1 2026 Earnings Call | Thu, May 07, 2026 · 8:00 AM ET | Replay |
| DiaMedica Therapeutics (NASDAQ:DMAC) Q4 2025 Earnings Call | Tue, Mar 31, 2026 · 8:00 AM ET | Replay |
| DiaMedica Therapeutics (NASDAQ:DMAC) Q3 2025 Earnings Call | Thu, Nov 13, 2025 · 8:00 AM ET | Replay |
| DiaMedica Therapeutics (NASDAQ:DMAC) Q2 2025 Earnings Call | Wed, Aug 13, 2025 · 8:00 AM ET | Replay |
| DiaMedica Therapeutics (NASDAQ:DMAC) Q1 2025 Earnings Call | Wed, May 14, 2025 · 8:00 AM ET | Replay |
| DiaMedica Therapeutics (NASDAQ:DMAC) Q3 2024 Earnings Call | Thu, Nov 14, 2024 · 8:00 AM ET | Replay |
| DiaMedica Therapeutics (NASDAQ:DMAC) Q2 2024 Earnings Call | Thu, Aug 08, 2024 · 8:00 AM ET | Replay |
| DiaMedica Therapeutics (NASDAQ:DMAC) Q1 2024 Earnings Call | Thu, May 09, 2024 · 8:00 AM ET | Replay |
All 25 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 · After close | −5.8% |
| Q2 2026 | Aug 10, 2026 · After close | +3.3% |
| Q1 2026 | May 6, 2026 · After close | +0.1% |
| Q4 2025 | Mar 31, 2026 | −3.3% |
| Q3 2025 | Nov 12, 2025 · After close | −14.1% |
| Q2 2025 | Aug 12, 2025 · After close | +14.9% |
| Q1 2025 | May 13, 2025 · After close | +0.5% |
| Q4 2024 | Mar 17, 2025 · Before open | +3.8% |
| Q3 2024 | Nov 13, 2024 · After close | −3.3% |
| Q2 2024 | Aug 7, 2024 · After close | +3.1% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 8, 2024 · After close | −6.3% |
| Q4 2023 | Mar 19, 2024 · After close | −1.8% |
| Q3 2023 | Nov 13, 2023 · After close | +6.8% |
| Q2 2023 | Aug 14, 2023 · After close | +4.4% |
| Q1 2023 | May 15, 2023 · After close | −10.8% |
| Q4 2022 | Mar 28, 2023 · After close | −3.3% |
| Q3 2022 | Nov 9, 2022 · After close | −1.6% |
| Q2 2022 | Aug 10, 2022 · After close | +9.8% |
| Q1 2022 | May 4, 2022 · After close | +2.8% |
| Q4 2021 | Mar 14, 2022 · After close | −0.4% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 38 slides | November 2026 |
| Investor Presentation (June 2026) | Investor deck | 39 slides | June 2026 |
| Q4 2025 Earnings Presentation | Earnings | 40 slides | Mar 31, 2026 |
| Q2 2025 Earnings Presentation | Earnings | 46 slides | Aug 13, 2025 |
| Technical Presentation (July 2025) | Technical | 21 slides | Jul 17, 2025 |
| Corporate Update (November 2024) | Corporate update | 6 slides | Nov 13, 2024 |
| Investor Presentation (June 2024) | Investor deck | 32 slides | Jun 26, 2024 |
| Technical Presentation (November 2023) | Technical | 6 slides | Nov 13, 2023 |
| Investor Presentation (June 2023) | Investor deck | 26 slides | Jun 21, 2023 |
| Corporate Update (May 2023) | Corporate update | 6 slides | May 22, 2023 |
All 14 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2021) | Investor deck | 25 slides | Sep 13, 2021 |
| Corporate Update (June 2021) | Corporate update | 15 slides | Jun 29, 2021 |
| Technical Presentation (May 2020) | Technical | 26 slides | May 13, 2020 |
| Corporate Update (June 2019) | Corporate update | 25 slides | Jun 19, 2019 |
Financings
| Raise | Date |
|---|---|
| Private placement of common shares Closed: US$30.1M raised · US$3.5 a share Buyers: Thomas von Koch (2,857,142 common shares through TomEnterprise Private AB for US$10,000,000; approximately 16.2% after closing); Trill AB (1,542,857 common shares for US$5,000,000; approximately 13.1% after closing); NFS/FMTC Roth IRA FBO Richard Jacinto II (400,000 common shares for US$1,400,000; approximately 9.6% after closing) Insiders: Certain non-management related parties acquired an aggregate of $16.8 million or 4,799,999 common shares Use of proceeds: To advance ongoing research and development activities | Jul 23, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$4.00 a share on Dec 6, 2018.
- Price
- US$4.00 a share
- Shares offered
- 4,100,000 common shares
- Offering size
- US$16.4 million
- Listing
- DMAC on the Nasdaq Capital Market
- Underwriter
- Craig-Hallum Capital Group
- Shares delivered
- On or about Dec 11, 2018
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Aug 27, 2018 |
| Filed publicly | Nov 9, 2018 |
| Amended 3 times | Newest Nov 28, 2018 |
| Shares registered with an exchange | Dec 3, 2018 |
| Declared effective by the SEC | Dec 6, 2018 |
| Final prospectus, with the price | Dec 10, 2018 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Dec 10, 2018 |
| EFFECT · Notice that a registration is effective | Dec 6, 2018 |
| CERT · Exchange's certificate of listing | Dec 6, 2018 |
| CORRESP · Letter to the SEC | Dec 4, 2018 |
| CORRESP · Letter to the SEC | Dec 4, 2018 |
| 8-A12B · Registration of shares for listing on an exchange | Dec 3, 2018 |
| CORRESP · Letter to the SEC | Nov 28, 2018 |
| S-1/A · Registration statement, amended | Nov 28, 2018 |
| UPLOAD · Letter from the SEC | Nov 27, 2018 |
| S-1/A · Registration statement, amended | Nov 27, 2018 |
All 24 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Nov 19, 2018 |
| S-1/A · Registration statement, amended | Nov 19, 2018 |
| UPLOAD · Letter from the SEC | Nov 15, 2018 |
| S-1 · Registration statement | Nov 9, 2018 |
| UPLOAD · Letter from the SEC | Nov 2, 2018 |
| DRS · Draft registration statement | Nov 1, 2018 |
| DRSLTR · Letter to the SEC with a draft | Nov 1, 2018 |
| DRS/A · Draft registration statement, amended | Oct 19, 2018 |
| DRSLTR · Letter to the SEC with a draft | Oct 18, 2018 |
| UPLOAD · Letter from the SEC | Oct 15, 2018 |
| DRSLTR · Letter to the SEC with a draft | Sep 17, 2018 |
| DRS/A · Draft registration statement, amended | Sep 17, 2018 |
| UPLOAD · Letter from the SEC | Sep 4, 2018 |
| DRS · Draft registration statement | Aug 27, 2018 |
Open IPO · From the cover of the final prospectus (424B4) filed Dec 10, 2018
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 500.0K | 0 | 0 |
| Cost of revenue | 39.0K | 30.0K | 25.0K | 24.0K | 21.0K | 21.0K | 0 | 4.00K | 2.21K | |
| Gross profit | -39.0K | -30.0K | -25.0K | -24.0K | -21.0K | -21.0K | 500.0K | -4.00K | -2.21K | |
| Research and development | 24.6M | 19.1M | 13.1M | 7.84M | 8.77M | 8.21M | 7.90M | 4.52M | 3.21M | 1.76M |
| Selling, general and administrative | 9.78M | 7.62M | 8.16M | 6.16M | 4.88M | 4.49M | 3.69M | 2.74M | 1.31M | 718.0K |
| Operating income | -34.4M | -26.7M | -21.3M | -14.0M | -13.6M | -12.7M | -11.6M | -6.76M | -4.52M | -2.48M |
| Depreciation and amortization | 43.0K | 39.0K | 30.0K | 25.0K | 24.0K | 21.0K | 21.0K | 15.0K | 4.00K | 2.21K |
| EBITDA | -34.4M | -26.6M | -21.2M | -14.0M | -13.6M | -12.7M | -11.6M | -6.75M | -4.51M | -2.48M |
| Interest expense | 353.0K | 82.0K | 229.0K | 119.0K | 0 | 0 | 48.4K | |||
| Income before tax | -32.7M | -24.4M | -19.3M | -13.6M | -13.6M | -12.3M | -10.6M | -5.65M | -4.26M | -2.20M |
| Income tax | 28.0K | 30.0K | 43.0K | 28.0K | 28.0K | 27.0K | 31.0K | 80.0K | -9.00K | 22.3K |
| Net income | -32.8M | -24.4M | -19.4M | -13.7M | -13.6M | -12.3M | -10.6M | -5.73M | -4.26M | -2.22M |
| Earnings per share, basic | -0.70 | -0.60 | -0.60 | -0.52 | -0.65 | -0.78 | -0.89 | -0.74 | -0.72 | -0.47 |
| Earnings per share, diluted | -0.65 | -0.78 | -0.89 | -0.74 | -0.72 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 15.6M | 3.02M | 4.54M | 4.73M | 4.71M | 7.41M | 3.88M | 16.8M | 1.35M | 1.74M |
| Short-term investments | 44.2M | 41.1M | 48.4M | 28.8M | 40.4M | 20.1M | 4.00M | 0 | 0 | 0 |
| Receivables | 258.0K | 236.0K | 369.0K | 82.0K | 130.0K | 340.0K | 823.0K | 780.0K | 80.0K | 52.0K |
| Inventory | 113.0K | 10.0K | 88.0K | 0 | 0 | 0 | ||||
| Current assets | 60.6M | 44.6M | 53.7M | 33.8M | 45.4M | 27.9M | 8.84M | 18.0M | 1.49M | 1.85M |
| Property, plant and equipment | 145.0K | 148.0K | 131.0K | 136.0K | 70.0K | 74.0K | 64.0K | 96.0K | 37.0K | 19.4K |
| Goodwill | 0 | 0 | 0 | |||||||
| Total assets | 61.4M | 46.3M | 54.2M | 34.4M | 45.6M | 28.1M | 9.05M | 18.3M | 1.80M | 1.87M |
| Accounts payable | 1.48M | 940.0K | 926.0K | 734.0K | 509.0K | 1.10M | 182.0K | 483.0K | 513.0K | 250.0K |
| Current liabilities | 5.13M | 5.39M | 2.79M | 2.17M | 1.52M | 2.03M | 1.32M | 1.30M | 1.00M | 627.0K |
| Long-term debt | 0 | 0 | 0 | |||||||
| Total debt | 240.0K | 340.0K | 400.0K | 469.0K | 52.0K | 118.0K | 178.0K | 23.0K | 200.5K | |
| Total liabilities | 5.26M | 5.63M | 3.10M | 2.57M | 1.53M | 2.08M | 1.44M | 1.31M | 1.00M | 627.0K |
| Shareholders' equity | 56.1M | 40.7M | 51.1M | 31.8M | 44.0M | 26.0M | 7.62M | 17.0M | 799.0K | 1.25M |
| Shares outstanding | 53.7M | 42.8M | 38.0M | 26.4M | 26.4M | 18.7M | 12.0M | 12.0M | 6.37M | 4.74M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -29.1M | -22.1M | -18.7M | -11.5M | -12.3M | -9.19M | -9.10M | -5.70M | -3.90M | -3.02M |
| Capital spending | -40.0K | -25.0K | -24.0K | -81.0K | -22.0K | -47.0K | -2.00K | -50.0K | -22.0K | -6.89K |
| Free cash flow | -29.1M | -22.1M | -18.8M | -11.6M | -12.3M | -9.23M | -9.10M | -5.75M | -3.92M | -3.03M |
| Cash from investing | -2.19M | 8.56M | -18.3M | 11.5M | -20.5M | -16.1M | -3.91M | -50.0K | -22.0K | -6.89K |
| Cash from financing | 43.9M | 12.0M | 36.8M | -6.00K | 30.1M | 28.8M | 70.0K | 21.2M | 3.54M | 4.59M |
| Dividends paid | 0 | 0 | 0 | |||||||
| Share buybacks | 28.9M | 75.0K | 21.2M | 3.54M | 4.59M | |||||
| Change in cash | 12.6M | -1.52M | -185.0K | 21.0K | -2.70M | 3.53M | -12.9M | 15.5M | -383.0K | 1.57M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2026 | Results | SEC |
| 4 · Change in ownership | Aug 12, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Aug 11, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 10, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 10, 2026 | Results | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 8-K · Current report | May 21, 2026 | Meeting outcome | SEC |
| 10-Q · Quarterly report | May 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 6, 2026 | Results | SEC |
| ARS · Annual report to shareholders | Apr 1, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 1, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 1, 2026 | Meeting notice | SEC |
| 8-K · Current report | Mar 30, 2026 | Results | SEC |
| 10-K · Annual report | Mar 30, 2026 | Annual report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 6, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 5, 2026 | Current report | SEC |
| 8-K · Current report | Dec 18, 2025 | Current report | SEC |
| 4 · Change in ownership | Dec 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 25, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Nov 13, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 7, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 3, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 3, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 15, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 4, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Sep 4, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 27, 2025 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Aug 25, 2025 | Other filings | SEC |
| 424B2 · Prospectus | Aug 22, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Aug 20, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Aug 18, 2025 | Other filings | SEC |
| 8-K · Current report | Aug 12, 2025 | Material contract | SEC |
| S-3 · Registration statement | Aug 12, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2025 | Results | SEC |
| EFFECT · Notice that a registration is effective | Aug 11, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Aug 6, 2025 | Other filings | SEC |
| 8-K · Current report | Aug 6, 2025 | Management or board change | SEC |
| UPLOAD · Letter from the SEC | Aug 5, 2025 | Other filings | SEC |
| S-3 · Registration statement | Aug 1, 2025 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 30, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 30, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 25, 2025 | Insider trade | SEC |
| D | Jul 24, 2025 | Other filings | SEC |
| 8-K · Current report | Jul 21, 2025 | Material contract | SEC |
| 8-K · Current report | Jul 17, 2025 | Current report | SEC |
| 4 · Change in ownership | Jun 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2025 | Insider trade | SEC |
| 8-K · Current report | May 15, 2025 | Meeting outcome | SEC |
| 10-Q · Quarterly report | May 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 13, 2025 | Results | SEC |
| 4 · Change in ownership | Apr 8, 2025 | Insider trade | SEC |
| ARS · Annual report to shareholders | Mar 28, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Mar 28, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Mar 28, 2025 | Meeting notice | SEC |
| 10-K · Annual report | Mar 17, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 17, 2025 | Results | SEC |
| 8-K · Current report | Mar 6, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Feb 24, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 24, 2025 | Insider trade | SEC |
| 8-K · Current report | Feb 24, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Feb 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 13, 2024 | Results | SEC |
| 8-K · Current report | Aug 7, 2024 | Results | SEC |
| 10-Q · Quarterly report | Aug 7, 2024 | Quarterly report | SEC |
| EFFECT · Notice that a registration is effective | Jul 19, 2024 | Other filings | SEC |
| 424B3 · Prospectus | Jul 18, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jul 16, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jul 15, 2024 | Other filings | SEC |
| S-3 · Registration statement | Jul 10, 2024 | Offer document | SEC |
| SC 13G · Big-stake notice | Jul 8, 2024 | Big-stake notice | SEC |
| D | Jul 2, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 2, 2024 | Other filings | SEC |
| 4 · Change in ownership | Jul 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 26, 2024 | Material contract | SEC |
| 8-K · Current report | Jun 26, 2024 | Current report | SEC |
| 4 · Change in ownership | Jun 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2024 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | May 24, 2024 | Offer document | SEC |
| 8-K · Current report | May 23, 2024 | Management or board change | SEC |
| 10-Q · Quarterly report | May 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2024 | Results | SEC |
| 8-K · Current report | Apr 10, 2024 | Management or board change | SEC |
| EFFECT · Notice that a registration is effective | Apr 10, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 4, 2024 | Other filings | SEC |
| ARS · Annual report to shareholders | Apr 4, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 4, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 4, 2024 | Meeting notice | SEC |
| UPLOAD · Letter from the SEC | Mar 26, 2024 | Other filings | SEC |
| S-3 · Registration statement | Mar 21, 2024 | Offer document | SEC |
| 10-K · Annual report | Mar 19, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 19, 2024 | Results | SEC |
| 4 · Change in ownership | Jan 23, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 16, 2023 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 13, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 13, 2023 | Results | SEC |
| 8-K · Current report | Sep 5, 2023 | Management or board change | SEC |
| 10-Q · Quarterly report | Aug 14, 2023 | Quarterly report | SEC |
| 8-K · Current report | Aug 14, 2023 | Results | SEC |
| 424B3 · Prospectus | Jul 10, 2023 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jul 10, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jul 5, 2023 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jul 5, 2023 | Other filings | SEC |
| S-3 · Registration statement | Jun 30, 2023 | Offer document | SEC |
| SC 13G/A · Big-stake notice, amended | Jun 27, 2023 | Big-stake notice | SEC |
| D | Jun 27, 2023 | Other filings | SEC |
| SC 13G/A · Big-stake notice, amended | Jun 27, 2023 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 27, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 27, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2023 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Jun 23, 2023 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Jun 23, 2023 | Insider trade | SEC |
| 8-K · Current report | Jun 21, 2023 | Material contract | SEC |
| 8-K · Current report | Jun 21, 2023 | Current report | SEC |
| 8-K · Current report | Jun 21, 2023 | Current report | SEC |
| 4 · Change in ownership | Jun 2, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 30, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 30, 2023 | Insider trade | SEC |
| 8-K · Current report | May 30, 2023 | Management or board change | SEC |
| 8-K · Current report | May 22, 2023 | Current report | SEC |
| 8-K · Current report | May 18, 2023 | Meeting outcome | SEC |
| 10-Q · Quarterly report | May 15, 2023 | Quarterly report | SEC |
| 8-K · Current report | May 15, 2023 | Results | SEC |
| D | Apr 18, 2023 | Other filings | SEC |
| 4 · Change in ownership | Apr 11, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 11, 2023 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 4, 2023 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 4, 2023 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 4, 2023 | Meeting notice | SEC |
| 10-K · Annual report | Mar 28, 2023 | Annual report | SEC |
| 8-K · Current report | Mar 28, 2023 | Results | SEC |
| PRE 14A · Preliminary proxy statement | Mar 17, 2023 | Meeting notice | SEC |
| 8-K · Current report | Mar 10, 2023 | Current report | SEC |
| 8-K/A · Current report, amended | Mar 10, 2023 | Management or board change | SEC |
| 4 · Change in ownership | Mar 6, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 6, 2023 | Insider trade | SEC |
| 8-K · Current report | Mar 6, 2023 | Management or board change | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 13, 2023 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 13, 2023 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 3, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2023 | Insider trade | SEC |
This page holds 200 of 429 filings. Open Filings
Cap table
Built by 6ix from DiaMedica Therapeutics Inc.’s releases · as of Nov 9, 2026
- Common shares
- 53,957,474
- Fully diluted
- 53,957,474
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 53,957,474 | Nov 9, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 9, 2026 | 53,957,474 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Richard Kuntz Other companies: Identiv, Inc. (Director · Since at least Oct 18, 2022); ZimVie Inc (Director · Since at least Mar 1, 2022); Rockley Photonics Holdings Ltd (Director · Aug 8, 2022 – Aug 8, 2022 · Past); Medtronic plc. (SVP & Chief Medical & Science · Jan 9, 2018 – Nov 5, 2021 · Past) | Director · Since at least May 30, 2023 |
| Amy Burroughs Other companies: Terns Pharmaceuticals, Inc. (Chief Executive Officer, Director · Since at least Feb 7, 2024); Tenaya Therapeutics, Inc. (Board Member · Since at least Dec 5, 2022) | Director · Jul 15, 2021 – Jan 3, 2023 · Past |
| Daniel O’Connor Other companies: Ambrx Biopharma Inc. (President and CEO, Director · Jan 1, 2023 – Mar 7, 2024 · Past); ZyVersa Therapeutics, Inc. (Director · Dec 20, 2021 – Dec 12, 2022 · Past) | Director · Since at least Feb 20, 2025 |
| James Parsons Other companies: Oncolytics Biotech Inc. (Director · Since at least Jan 1, 2026); Trillium Therapeutics Inc (Chief Financial Officer · Jan 1, 2021 – Nov 17, 2021 · Past) | Chairman of the Board · Since at least Dec 6, 2018 |
| Julie Krop Other companies: Aquestive Therapeutics, Inc. (Aquestive Director, and Chief Medical Officer of DiaMedica Therapeutics, Inc. · Since at least Feb 10, 2021); AMAG Pharmaceuticals Inc (Chief Medical Officer · Jun 1, 2015 – Mar 2, 2020 · Past) | Chief Medical Officer · Since at least Aug 11, 2025 |
| Masuoka K Lorianne Other companies: Opiant Pharmaceuticals Inc (Director · Mar 18, 2021 – Mar 2, 2023 · Past); Marinus Pharmaceuticals Inc (Chief Medical Officer · Dec 6, 2017 – Aug 21, 2019 · Past) | Chief Medical Officer · Jan 22, 2024 – Jan 22, 2024 · Past |
| David Wambeke Other companies: NeuroOne Medical Technologies Corporation (Chief Business Officer · Since at least Mar 1, 2026) | Chief Business Officer · Since at least Apr 10, 2023 |
| Scott Kellen Other companies: Kips Bay Medical Inc (COO, CFO, VP of Finance & Secy · Feb 10, 2011 – Mar 10, 2015 · Past) | Chief Financial Officer · Since at least Dec 6, 2018 |
| Tanya Lewis Other companies: Replimune Group, Inc. (Chief Dev. Op. Officer · Apr 1, 2022 – Jun 13, 2023 · Past) | Director · Since at least Mar 1, 2023 |
| Ambarish Shah | Chief Technology Officer · Since at least Nov 5, 2026 |
All 23 people
| Person | Seat |
|---|---|
| Charles Semba | Director · Since at least Jul 15, 2021 |
| Dietrich John Pauls | President & CEO, Director · Since at least Dec 6, 2018 |
| Dominic Cundari | Chief Commercial Officer · Since at least Feb 1, 2022 |
| Harry W Alcorn Jr | SVP, Clinical Operations · Dec 6, 2018 – Sep 15, 2021 · Past |
| Julie VanOrsdel Daves | SVP Clinical Development Oper. · Sep 13, 2022 – Jun 1, 2023 · Past |
| Kirsten L Gruis | Chief Medical Officer · Jan 3, 2022 – Jun 1, 2023 · Past |
| Michael Giuffre | Director · Since at least Nov 5, 2026 |
| Randall Michael Giuffre | Director · Since at least Dec 6, 2018 |
| Richard D Pilnik | Director · Dec 6, 2018 – Apr 7, 2025 · Past |
| Rick Pauls | President & CEO · Since at least Oct 22, 2026 |
| Sydney A Gilman | VP, Regulatory Affairs · Nov 1, 2019 – Jul 28, 2021 · Past |
| Todd A Verdoorn | Chief Scientific Officer · Dec 6, 2018 – Jun 24, 2019 · Past |
| Zhenyu Xiao | Director · Dec 6, 2018 – Jun 24, 2019 · Past |
Log in to ask 6ix AI your own questions about DiaMedica Therapeutics Inc.